ArticleHepatology communications2022
Presence of Liver Inflammation in Asian Patients With Chronic Hepatitis B With Normal ALT and Detectable HBV DNA in Absence of Liver Fibrosis.
Article in Hepatology communications, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 46 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
46 citing papers in PubMed, 70 citations in OpenAlex.
- Comparison of clinical practice guidelines for chronic hepatitis B: natural history classification and treatment initiation.Clinical and molecular hepatology · 2026Review
- KASL clinical practice guidelines for management of chronic hepatitis B Endorsed by the East Asia Liver Alliance (EALA).Clinical and molecular hepatology · 2026Article
- Spatial-quantitative profiling of intrahepatic HBsAg heterogeneity and clustered distribution in chronic HBV infection.JHEP reports : innovation in hepatology · 2026Article
- Heterogeneity Analysis of HBeAg-Positive Chronic Hepatitis B Patients with Ultra-High Viral Load (HBV DNA ≥ 7.0 logJournal of clinical medicine · 2026Article
- Indeterminate Phase/Grey Zone of Chronic Hepatitis B: Clinical Features, Outcomes and Molecular Insights.Liver international : official journal of the International Association for the Study of the Liver · 2026Review
- The inflammatory state of tumor peripheral liver tissue affects hepatocellular carcinoma progression and prognosis.Discover oncology · 2026Article
- Clinical and histopathological features of chronic hepatitis B with normal alanine aminotransferase levels with or without concomitant non-alcoholic fatty liver disease.Frontiers in medicine · 2026Article
- Impact of Alanine Transaminase Thresholds on Treatment Eligibility of Patients with Chronic Hepatitis B: A Cross-sectional Study of the China Registry of Hepatitis B.Journal of clinical and translational hepatology · 2025Article
- Histopathological Features and Antiviral Efficacy in Patients Over 30 Years Old with Chronic Hepatitis B in the Indeterminate Phase.The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology · 2025Article
- Association Between Viral Replication Activity and Postoperative Recurrence of HBV-Related Hepatocellular Carcinoma.Alimentary pharmacology & therapeutics · 2025Observational
- Noninvasive diagnosis model for predicting significant liver inflammation in patients with chronic hepatitis B in the immune-tolerant phase.Scientific reports · 2025Article
- Progress towards "The Treat-All Approach" for hepatitis B.Translational gastroenterology and hepatology · 2025Article
- Correspondence to letter to the editor on "Non-linear association between liver fibrosis scores and viral load in patients with chronic hepatitis B".Clinical and molecular hepatology · 2025Article
- HBV-Induced Carcinogenesis: Mechanisms, Correlation With Viral Suppression, and Implications for Treatment.Liver international : official journal of the International Association for the Study of the Liver · 2025Review
- Virological response and predictive factors for antiviral treatment in chronic HBV-related liver disease with low ALT and high HBV DNA.Frontiers in immunology · 2025Article
- Cost-effectiveness analysis of oral antiviral therapy in patients with indeterminate chronic hepatitis B infection.Translational gastroenterology and hepatology · 2025Article
- Prevalence and Serological Predictors of Liver Fibrosis in Vietnamese Chronic Hepatitis B Patients with Persistently Normal or Mildly Elevated Aminotransferase Level.Medical archives (Sarajevo, Bosnia and Herzegovina) · 2025Article
- Elimination of hepatitis B as a public health threat: Addressing the challenge and taking action.World journal of hepatology · 2024Article
- The potential value of fatty acid binding protein 1 in Chronic HBV-related liver disease progression assessment.BMC infectious diseases · 2024Article
- Non-linear association between liver fibrosis scores and viral load in patients with chronic hepatitis B.Clinical and molecular hepatology · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Liver biopsies are recommended to exclude significant liver inflammation in patients with chronic hepatitis B (CHB) with elevated HBV DNA but without other indications for antiviral treatment. We aimed to investigate the proportions and determinants of significant inflammation in Asian patients with CHB with detectable HBV DNA. We conducted a cross-sectional study that retrospectively included 581 patients with CHB with detectable HBV DNA who had undergone liver biopsy. Liver inflammation and fibrosis were staged by Scheuer's classification. Significant inflammation and significant fibrosis were defined as G ≥ 2 and S ≥ 2, respectively. There were 179 (30.8%) patients with alanine aminotransferase (ALT) < 1 × upper limit of normal (ULN), 205 (35.3%) patients with ALT 1-2 × ULN, and 197 (33.9%) patients with ALT > 2 × ULN. A total of 397 (68.3%) patients had significant inflammation, and 340 (58.5%) patients had significant fibrosis. Significant inflammation was found in 85% of patients with significant fibrosis and in 44.8% of patients without significant fibrosis. Furthermore, 28.7% of patients with CHB with detectable HBV DNA and normal ALT in the absence of significant fibrosis had significant inflammation. Moderate HBV DNA (5-7 log
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.